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Abstract
 
The B cell antigen receptor (BCR) is a large complex that consists of a disulfide-linked tet-
ramer of two transmembrane heavy (
 
m
 
) chains and two light (
 
l
 
 or 
 
k
 
) chains in association with
a heterodimer of Ig
 
a
 
 and Ig
 
b
 
. Kaposi’s sarcoma–associated herpesvirus (KSHV) encodes a
transforming protein called K1, which has structural and functional similarity to Ig
 
a
 
 and Ig
 
b
 
.
We demonstrate that K1 downregulates the expression of BCR complexes on the surface. The
NH
 
2
 
-terminal region of K1 specifically interacts with the 
 
m
 
 chains of BCR complexes, and this
interaction retains BCR complexes in the endoplasmic reticulum, preventing their intracellular
transport to the cell surface. Thus, KSHV K1 resembles Ig
 
a
 
 and Ig
 
b
 
 in its ability to induce sig-
naling and to interact with 
 
m 
 
chains of the BCR. However, unlike Ig
 
a
 
 and Ig
 
b
 
, which interact
with 
 
m 
 
chains to direct BCR complexes to the cell surface, K1 interacts with 
 
m
 
 chains to block
the intracellular transport of BCR complexes to the cell surface. These results demonstrate a
unique feature of the K1 transforming protein, which may confer virus-infected cells with a
long-term survival advantage.
Key words: Kaposi’s sarcoma–associated herpesvirus • K1 • B cell antigen receptor • 
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Introduction
 
During biosynthesis, transmembrane proteins are translo-
cated into the endoplasmic reticulum (ER)
 
1
 
 lumen and be-
come anchored in the membrane. In the case of multipro-
tein complexes, all components should assemble before
transport via the Golgi complex to the cell surface can oc-
cur. As an important step in quality control, incorrectly as-
sembled protein complexes or assembly intermediates are
retained in the ER, ensuring that only functional proteins
become expressed on the cell surface (1, 2).
The B cell antigen receptor (BCR) consists of a disul-
fide-linked tetramer of two transmembrane mIg heavy (
 
m
 
)
chains in covalent association with two light (
 
l
 
 or 
 
k
 
) chains
(3, 4). In addition, the BCR complex contains a disulfide-
linked heterodimer formed by Ig
 
a
 
 and Ig
 
b
 
, which serves
to direct the receptor complexes to the cell surface and to
provide receptor signaling capacity (5, 6). Analysis of se-
quence elements responsible for the signaling properties of
the transducing subunits of BCR has led to the identifica-
tion of the immunoreceptor tyrosine-based activation mo-
tif (ITAM [5]). This motif consists of six conserved amino
acid residues spaced precisely over an 
 
z
 
26 amino acid se-
quence, D/Ex
 
7
 
D/Ex
 
2
 
YxxLx
 
7
 
YxxL/I, and a single copy of
this motif is present in the cytoplasmic region of Ig
 
a
 
 and
Ig
 
b
 
 (5). Because the Ig
 
a
 
 and Ig
 
b
 
 heterodimer is essential
for the signaling capacity of the receptor, it is essential that
only fully assembled BCR complexes appear on the cell
surface. Therefore, the expression levels of the individual
components as well as assembly of oligomers and transport
through intracellular compartments are subject to various
intracellular control mechanisms.
Association of the Ig
 
a
 
 and Ig
 
b
 
 heterodimer is essential
for intracellular transport and plasma membrane deposition
of newly synthesized mIg molecules. The site of intracellu-
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S
 
-transferase; ITAM, immunore-
ceptor tyrosine-based activation motif; KSHV, Kaposi’s sarcoma–associ-
ated herpesvirus; LMP2A, latent membrane protein 2A; PEL, primary
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lar retention of mIg in absence of this heterodimer is the
ER. This retention has been found to be dictated by two
regions of the 
 
m
 
 chain of mIg, the transmembrane region
and the first constant region. The transmembrane region of
the 
 
m 
 
chain controls its interaction with the ER chaperone
calnexin (7), whereas the first constant domain of the 
 
m
 
chain is important for association with the ER-resident Ig
heavy chain binding protein (8). These interactions of the
 
m
 
 chain with the ER-resident proteins have been shown to
be an important control mechanism for surface expression
of the BCR complexes (7, 9).
A new human tumor virus, called Kaposi’s sarcoma–
associated herpesvirus (KSHV) or human herpesvirus 8
(HHV8), has been consistently identified in Kaposi’s sar-
coma tumors from HIV-positive and HIV-negative pa-
tients (10–12). KSHV has also been identified in primary
effusion lymphoma (PEL) and immunoblast variant of Cas-
tleman’s disease, which are of B cell origin (10, 11, 13).
The genomic sequence indicates KSHV to be a 
 
g
 
 herpesvi-
rus that is closely related to herpesvirus saimiri (14, 15) and
the recently isolated rhesus monkey rhadinovirus (16–18).
KSHV contains the first open reading frame called K1
(19). K1 gene is expressed at low levels in PEL, and its ex-
pression is significantly induced during the lytic viral life
cycle (20). The K1 protein is predicted to have a signal
peptide sequence at the NH
 
2
 
 terminus, an extracellular do-
main, a transmembrane domain, and a short cytoplasmic
tail at the COOH terminus (19–22). The predicted extra-
cellular domain of the K1 protein demonstrates a regional
homology in the primary amino acid sequence with the
variable region of the 
 
l
 
 chain of the Ig light chain (19, 21).
In addition, similar to Ig
 
a
 
 and Ig
 
b
 
, the cytoplasmic region
of K1 contains a functional ITAM that is capable of trans-
ducing signals to elicit cellular activation events (23, 24).
In this report, we demonstrate that the NH
 
2
 
-terminal re-
gion of K1 specifically interacts with the 
 
m
 
 chains of BCR
complexes, and that this interaction inhibits their intracel-
lular transport, resulting in downregulation of BCR surface
expression.
 
Materials and Methods
 
Cell Culture and Transfection.
 
BJAB cells were grown in
RPMI medium supplemented with 10% FCS, and 293T cells
were grown in DME medium supplemented with 10% FCS. A
fusin lipofection (Boehringer) transfection procedure was used for
transient expression in 293T cells. The pBabe-K1 and pcDNA-
K1/CD8 chimera constructs (20 
 
m
 
g) were introduced into BJAB
cells by electroporation at 250 V and 960 
 
m
 
F in serum-free DME
medium. After a 48-h incubation, the cells were cultured with se-
lection medium containing 5 
 
m
 
g/ml of puromycin or 2 mg/ml of
G418 (GIBCO BRL) for 5 wk.
 
Plasmid Constructions.
 
The AU1-tagged K1 and its mutant
genes were cloned into the
 
 
 
EcoRI and SalI cloning sites of pBabe-
puro retroviral vector. The flag-tagged and myc-tagged K1 genes
have been described previously (19, 24). pEF-
 
m
 
 expression vector
was constructed using the human 
 
m
 
 cDNA provided by Dr. P.
Leder (Harvard Medical School, Boston, MA) and Dr. M.C. Nus-
senzweig (The Rockefeller University, New York, NY). The ex-
 
tracellular and/or transmembrane regions of the human CD8
 
a
 
were amplified by PCR and replaced with those of the K1. For
stable expression, the EcoRI and XhoI DNA fragment containing
the K1/CD8 chimera sequence was cloned into pcDNA3-Neo
(Invitrogen). A new pDEF3–glutathione 
 
S
 
-transferase (GST)-
AU1 fusion plasmid was constructed to contain the CMV early
promoter and multicloning sites linked to the GST gene, which is
tagged with an AU1 epitope at its COOH terminus. To construct
the K1/GST fusion expression construct, the NH
 
2
 
-terminal re-
gion of K1 was PCR amplified and fused in frame into the
pDEF3-GST-AU1 vector. All PCR-amplified DNA fragments
were completely sequenced to verify the presence of the correct
sequence and the absence of any other changes.
 
Metabolic Labeling, Immunoprecipitation, and Immunoblot.
 
For
metabolic labeling, cells were rinsed three times with PBS,
washed once with labeling medium (RPMI minus methionine
and cysteine plus 10% dialyzed FCS), and then incubated with 5
ml of the same medium containing 100 
 
m
 
Ci of [
 
35
 
S]methionine
and [
 
35
 
S]cysteine (NEN Life Science Products) for 16 h. For
pulse-chase analysis, cells were labeled for 30 min and chased for
1, 3, or 4 h. Cells were harvested and lysed with lysis buffer (0.15
M NaCl, 1% NP-40 or 1% digitonin, and 50 mM Hepes buffer,
pH 8.0) containing 1 mM Na
 
2
 
VO
 
3
 
, 1 mM NaF, and protease in-
hibitors (leupeptin, aprotinin, PMSF, and bestatin). Immunopre-
cipitation was performed with 1:500 diluted antibody together
with 30 
 
m
 
l of protein A/G agarose beads. Endoglycosidase H
(Endo H) digestion was performed for 2 h with washed immuno-
precipitates as recommended by the manufacturer’s protocol
(Boehringer). For protein immunoblots, polypeptides in cell ly-
sates corresponding to 10
 
5
 
 cells were resolved by SDS-PAGE and
transferred to a nitrocellulose membrane filter. Immunoblot de-
tection was performed with a 1:1,000 or 1:3,000 dilution of pri-
mary antibody using the enhanced chemiluminescence system
(Amersham Pharmacia Biotech). Mouse anti-AU1 ascites were
purchased from BABCO.
 
Immunofluorescence and Confocal Microscopy.
 
Slides for cells
grown in suspension were prepared by cytospin centrifugation.
After air drying, cells were fixed with cold acetone for 15 min
and blocked with 10% goat serum in PBS for 30 min. Cells were
stained with 1:100 diluted primary antibody in PBS containing
1% gelatin for 30 min. After incubation, cells were washed exten-
sively with PBS and incubated with 1,100 diluted Alexa 568–
conjugated secondary antibody (Vector Laboratories) and Alexa
488–conjugated Con A for ER-specific staining (Molecular
Probes) in PBS containing 1% gelatin for 30 min at room tem-
perature. For Golgi compartment staining, cells were metaboli-
cally labeled with 5 
 
m
 
g/ml boron dipyrromethane (BODIPY)
C5FL-ceramide for 30 min as recommended by the manufac-
turer’s protocol (Molecular Probes). Finally, cells were washed
three times with PBS and mounted in mounting media (Vector
Laboratories). Confocal microscopy was performed using a Leica
TCS-SP laser scanning microscope fitted with a 100
 
3 
 
Leica ob-
jective (Planapochromatic; 1.4 numerical aperture), and using the
Leica image software. Images were collected at 512 
 
3
 
 512 pixel
resolution. The stained cells were optically sectioned in the
z-axis, and the images in the different channels (photomultiplier
tubes) were collected simultaneously. The step size in the z-axis
varied from 0.2–0.5 
 
m
 
m to obtain 30–50 slices per image filed.
The images were transferred to a Macintosh G3 computer (Apple
Computer, Inc.), and National Institutes of Health Image v1.61
software was used to render the images.
 
Flow Cytometry Analysis.
 
5 
 
3 
 
10
 
5 
 
cells were washed with
RPMI medium containing 10% FCS, and were incubated with 
13
 
Lee et al.
 
FITC-conjugated or PE-conjugated mAbs for 30 min at 4
 
8
 
C. Af-
ter washing, each sample was fixed with 2% paraformaldehyde so-
lution, and flow cytometry analysis was performed with a FAC-
Scan™ (Becton Dickinson). W6/32 antibody for MHC class I,
TU39 antibody for HLA-DR, RPA-T8 antibody for CD8, B43
antibody for CD19, HIB22 antibody for CD22, CB3.1 antibody
for Ig
 
b
 
, and goat anti–mouse total IgG antibody for isotype con-
trol used for FACS
 
®
 
 and confocal immunofluorescence analyses
were obtained from Becton Dickinson and BD PharMingen.
Goat anti–human IgM and rabbit anti–goat antibody were pur-
chased from Southern Biotechnology Associates, Inc.
 
Results
 
Downregulation of Surface Expression of BCR Complexes
by K1. 
 
To investigate K1 function in lymphocyte signaling,
EBV- and KSHV-negative BJAB cells were used to estab-
lish a stable cell line expressing the K1 gene in the absence
of the remainder of KSHV viral genome. The full-length
K1 gene was modified to encode an AU1 epitope tag at the
COOH terminus, and was cloned into the retroviral vector
pBabe-puro. After electroporation of this retroviral vector
into BJAB cells, control BJAB/babe and BJAB/K1 cell lines
were selected by growth in medium containing 5 
 
m
 
g/ml of
puromycin. To demonstrate expression of the K1 gene in
puromycin-resistant cells, radioactively labeled cell lysates
were used for immunoprecipitation with an anti-AU1 anti-
body. A 55-kD K1 was detected only from BJAB cells con-
taining the K1
 
 
 
gene (Fig. 1 A). As shown in fibroblast cells
(19), the expression of K1 also resulted in morphological
changes of BJAB cells; BJAB/K1 cells were irregularly
shaped and had a rough surface, whereas control BJAB cells
were roundly shaped and had a smooth surface (Fig. 1 B).
When surface expression of lymphocyte antigen was ex-
amined, a dramatic reduction in the surface expression of
IgM and Ig
 
b
 
 was observed in BJAB/K1 compared with
control BJAB/babe cells (Fig. 2). In contrast, CD11a,
CD18, CD19, CD21, CD22, CD29, CD30, CD40,
CD50, CD54, B7-1, B7-2, MHC class I, and HLA-DR
did not show detectable changes in their surface expression
under the same conditions (Fig. 2; data not shown). Three
independently constructed BJAB/K1 cell lines showed the
same results (data not shown). These results demonstrate
that the expression of K1 in BJAB cells downregulates sur-
face expression of BCR components IgM and Ig
 
b
 
 in a spe-
cific manner.
 
The NH
 
2
 
-terminal Region of K1 Is Required for BCR
Downregulation.
 
To identify the region of K1 that ac-
counted for downregulation of BCR surface expression,
BJAB cells containing a chimeric protein between K1 and
human CD8
 
a
 
 were established by electroporation with an
expression vector. In the chimera K1/CD8-Ex, the extra-
cellular region of K1 was replaced with that of CD8
 
a
 
; in
the chimera K1/CD8-Tm, the transmembrane region of
K1 was replaced with that of CD8
 
a
 
; and in the chimera
K1/CD8-Ex
 
1
 
Tm, the extracellular and transmembrane
regions of K1 were replaced with those of CD8
 
a
 
 (Fig. 3).
Figure 1. Expression of K1
and morphological change in-
duced by K1 expression. (A) K1
expression. Radioactively labeled
lysates of BJAB/babe and BJAB/
K1 cells were used for immuno-
precipitation (IP) with an anti-
AU1 (aAU1) antibody. Autora-
diography was detected after 2 d
of exposure. Arrow indicates K1
protein. (B) Morphological
change induced by K1. Differen-
tial interference contrast image
obtained with a Leica TCS-SP
laser scanning microscope. Orig-
inal magnification: 3400.
Figure 2. Downregulation of IgM and
Igb surface expression in BJAB/K1 cells.
Live BJAB/babe (BJAB) and BJAB/K1 cells
were stained for the surface expression of
lymphocyte antigens as described in Materi-
als and Methods. 2 3 105 events were col-
lected on a FACScan™ flow cytometer
(Becton Dickinson). As a control, a histo-
gram of each lymphocyte antigen staining
(shaded) is overlaid with a dotted-line histo-
gram of isotype antibody control. The mean
value of the relative level of surface expres-
sion of each lymphocyte antigen is presented
inside of the figure. The data were repro-
duced in three independent experiments. 
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In addition, CD8-Ex
 
1
 
Tm containing its extracellular and
transmembrane region was included as a control (Fig. 3).
Comparable levels of CD8 surface expression of transfected
cells were detected (data not shown). However, upon ex-
pression of CD8-Ex
 
1
 
Tm, K1/CD8-Ex, and K1/CD8-
Ex
 
1
 
Tm chimeras, BCR did not undergo appreciable lev-
els of downregulation (Fig. 3). In contrast, K1/CD8-Tm
expression induced significant levels of BCR downregula-
tion, as was seen with a wild-type K1 (Fig. 3).
To further examine whether the COOH-terminal
ITAM sequence of K1 contributed to the downregulation
of BCR surface expression, the tyrosine residues at posi-
tions 271, 272, and/or 282 were replaced with phenylala-
nines, called K1/YY/FF, K1/Y
 
282
 
F, and K1/TYF (refer-
ence 23; Fig. 4). In addition, deletion mutations were
introduced into the cytoplasmic region of K1, resulting in
the K1/D1, K1/D2, and K1/D3 constructs (Fig. 4). As de-
scribed previously (23), K1/D1 contains the negatively
charged conserved region with a proximal YXXL motif,
K1/D2 contains only the negatively charged conserved re-
gion, and K1/D3 contains both YXXL/P motifs without
the negatively charged conserved region. After electropora-
tion of retroviral vectors containing these mutants, BJAB
cells were selected by growth in medium containing 5 
 
m
 
g/
ml of puromycin, and were examined for their IgM surface
expression by flow cytometry. Similar to wild-type K1, all
these K1 mutants induced drastic downregulation of BCR
surface expression (Fig. 4). These results demonstrate that
the NH
 
2
 
-terminal region of K1, but not the transmem-
brane and COOH-terminal regions, is necessary for the
downregulation of BCR surface expression.
Figure 3. The NH2-terminal region of K1 is required for downregula-
tion of BCR surface expression. (A) Summary of BCR downregulation
by K1/CD8 chimeras. K1 and CD8a are indicated by hatched and open
boxes, respectively. Ex, extracellular region; Tm, transmembrane; Cyt,
cytoplasmic region. (B) IgM surface expression. Live BJAB, BJAB/K1,
BJAB/K1/CD8-Ex1Tm, BJAB/K1/CD8-Ex, BJAB/K1/CD8-Tm, and
BJAB/CD8-Ex1Tm cells were stained for the surface expression of IgM
as described in Materials and Methods. As a control, a histogram of each
cell line (shaded) is overlaid with a dotted-line histogram of an anti–
mouse total IgG antibody as isotype control. The mean value of the rela-
tive level of IgM surface expression is presented inside of the figure. The
data were reproduced in three independent experiments. Ex, extracellular
region; Tm, transmembrane.
Figure 4. The COOH-terminal ITAM of K1 is not required for
downregulation of BCR surface expression. (A) Summary of the carboxyl
ITAM mutants of K1. Ex, extracellular region; Tm, transmembrane; Cyt,
cytoplasmic region; Y, tyrosine; F, phenylalanine; L, leucine; P, proline.
(B) IgM surface expression. Live BJAB, BJAB/K1, BJAB/K1/D1, BJAB/
K1/D2, BJAB/K1/D3, BJAB/K1/YY/FF, BJAB/K1/Y282F, and BJAB/
K1/TYF cells were stained for the surface expression of IgM as described
in Materials and Methods. As a control, a histogram of each cell line
(shaded) is overlaid with a dotted-line histogram of an anti–mouse total
IgG antibody as isotype control. The mean value of the relative level of
IgM surface expression is presented inside of the figure. The data were re-
produced in two independent experiments.15 Lee et al.
The Retention of BCR Components in the ER of Cells Ex-
pressing K1. We investigated whether K1 expression also
affected intracellular localization of BCR components.
BJAB and BJAB/K1 cells were stained with antibodies spe-
cific for Iga, Igb, or m chains, followed by reaction with
Alexa 568–conjugated secondary antibody (red). Confocal
microscopy of the immunostained cells showed that the lo-
calization of m chains was significantly affected by K1 ex-
pression. m chains were primarily localized in the plasma
membrane in control BJAB cells (Fig. 5 A). In contrast,
Figure 5. Altered localization of BCR complexes in K1-expressing cells. BJAB/
babe (BJAB) cells and BJAB/K1 cells were fixed and labeled with (A) anti-m, (B)
anti-Iga, or (C) anti-Igb antibody. The m, Iga, and Igb proteins were detected with
a secondary antibody conjugated with Alexa 568 (red). The ER and Golgi compart-
ment were detected with Alexa 488–conjugated Con A (green) and BODIPY
C5FL-ceramide (green), respectively. Yellow color indicates colocalization of the
red and green labels. The data were reproduced in three independent experiments.16 Downregulation of BCR Complexes by KSHV K1
they were predominantly localized at the perinuclear re-
gion in BJAB/K1 cells (Fig. 5 A). Because this perinuclear
staining pattern is similar to that obtained when the ER is
visualized, we further defined the localization of m chains,
using Alexa 488–conjugated (green) Con A for ER-specific
staining or BODIPY C5FL-ceramide for Golgi compart-
ment–specific staining. Confocal microscopy showed that
m chains in K1-expressing cells were primarily localized in
the ER but not in the Golgi compartment (Fig. 5 A).
When an anticalnexin antibody for ER localization (7) and
an anti–Golgi compartment 58K antibody for Golgi com-
partment localization (25) were used for immunofluores-
cence tests, essentially the same results were obtained (Fig.
6). Similar to m chains, Iga and Igb were predominantly
localized in the ER in BJAB/K1 cells, whereas they were
present in both the plasma membrane and the ER in BJAB
cells (Fig. 5, B and C). In addition, confocal microscopy
with several different antibodies showed a lower level of
Igb detection in BJAB/K1 cells than in BJAB cells (Fig. 5
C). These results demonstrated that K1 expression led to
the retention of BCR subunits in the ER.
Maturation and Assembly of BCR Components. ER-local-
ized glycoproteins bear immature N-linked glycans, which
mature during intracellular transport to the medial-Golgi
compartment (26). To investigate the maturation of BCR
components, BJAB and BJAB/K1 cells were metabolically
labeled with [35S]methionine and [35S]cysteine for 30 min,
chased for 1 and 4 h, and lysed by 1% NP-40 detergent. In-
dividual BCR components, Iga, Igb, and m chains, were
precipitated with their specific antibodies. In addition to a
70-kD m chain protein, a 72-kD mature form of m chain
was detected during a chase period in BJAB cells but not in
BJAB/K1 cells, indicating that the m chains of BCR un-
derwent maturation in BJAB cells but not in BJAB/K1
cells (Fig. 7). Iga has been shown to migrate with an appar-
ent molecular weight of 37, 40, and 43 kD (27). Unlike m
chains, no specific change of Iga and Igb maturation was
detected in K1-expressing cells (Fig. 7). These results dem-
onstrated that K1 expression specifically blocked the matu-
ration of the m chains of BCR subunits.
To investigate the effect of K1 on BCR assembly, BJAB
and BJAB/K1 cells were metabolically labeled with [35S]me-
thionine and [35S]cysteine for 30 min, chased for 1 and 3 h,
and lysed by 1% digitonin detergent to preserve assembled
BCR complexes. Assembled BCR complexes were then
precipitated with antibody specific to Iga, Igb, or m chain.
Similar amounts of Iga, Igb, or m chain were detected in
each immune complex of BJAB and BJAB/K1 cells, sug-
gesting that K1 did not significantly affect BCR assembly
(Fig. 8). However, consistent with immunoprecipitation in
NP-40 lysis buffer (Fig. 7), a maturation of m chains was not
detected in K1-expressing cells, whereas it was evident in
control BJAB/babe cells (Fig. 8 B). These results indicated
that although K1 did not affect the level of BCR assembly
and expression, it specifically inhibited maturation of m
chains by retaining BCR complexes in the ER.
Figure 6. Localization of IgM.
BJAB/babe (BJAB) cells and
BJAB/K1 cells were fixed and
colabeled with anti-m antibody
(am) together with anticalnexin
(acalnexin) or anti–Golgi com-
partment 58K (aGolgi 58K) an-
tibody. The m chain was de-
tected with a secondary antibody
conjugated with Alexa 568 (red).
Calnexin for ER localization and
58K for Golgi compartment lo-
calization were detected with a
secondary antibody conjugated
with Alexa 488 (green). Yellow
color at merged images indicates
colocalization of the red and
green labels. The data were re-
produced in two independent
experiments.
Figure 7. Maturation of BCR components. BJAB/babe (BJAB) and
BJAB/K1 cells were metabolically labeled with [35S]methionine and
[35S]cysteine for 30 min and chased for 1 and 4 h. Cells were lysed with
1% NP-40 buffer, and radioactively labeled lysates of BJAB/babe cells
and BJAB/K1 cells were used for immunoprecipitation with an anti-m,
anti-Iga, or anti-Igb antibody. Only the part of the gel displaying the m
chain, Iga, or Igb is shown. The data were reproduced in three inde-
pendent experiments.17 Lee et al.
Endo H Sensitivity of BCR Components. Carbohydrate
moieties of BCR complexes contain high mannose-type
oligosaccharides in the ER that are susceptible to Endo H
digestion. However, after transport to the medial-Golgi
compartment, their carbohydrate moieties acquire resis-
tance to cleavage by Endo H (28). To further investigate
the effect of K1 on the intracellular transport of BCR com-
plexes, BJAB control cells and BJAB/K1 cells were meta-
bolically labeled with [35S]methionine and [35S]cysteine for
30 min and chased for 1, 3, or 4 h. BCR components, m
chains, Iga, and Igb, were precipitated with their specific
antibodies. Half of immune precipitates were subjected to
Endo H digestion and separated by SDS-PAGE. As shown
in Fig. 8, m chains remained Endo H sensitive in BJAB/K1
cells, whereas they acquired resistance to Endo H cleavage
in BJAB cells. In contrast, Iga and Igb underwent Endo H
digestion in both cells (Fig. 8 B). As all three species of Iga
were sensitive to Endo H digestion, it also suggested that
maturation of Iga may be different from that of m chains.
In summary, these results further confirmed that K1 re-
tained BCR complexes in the ER.
ER Localization of K1. To investigate the role of K1 in
the ER retention of BCR complexes, we examined the
subcellular localization of K1 by indirect immunofluores-
cence and confocal microscopy. BJAB cells were trans-
fected with an expression vector containing the epitope-
tagged K1 gene, the flag-K1 containing a flag epitope at the
NH2 terminus (24), or the K1-myc containing a myc
epitope at the COOH terminus (19). An expression vector
containing the human CD4 gene was included as a control.
Figure 8. Assembly and Endo H sensitivity of BCR complexes. (A)
Endo H sensitivity of m chains. BJAB/babe (BJAB) and BJAB/K1 cells
were metabolically labeled with [35S]methionine and [35S]cysteine for 30
min and chased for 1 and 4 h. Cells were lysed with 1% digitonin lysis
buffer, and radioactively labeled lysates were used for immunoprecipita-
tion with an anti-m. m chain immunoprecipitates were untreated (2) or
treated (1) with Endo H before SDS-PAGE. Only the part of the gel dis-
playing the m chains is shown. The asterisk indicates the Endo H–sensi-
tive forms of m chains. (B) Assembly of BCR and Endo H sensitivity of
Iga and Igb. BJAB and BJAB/K1 cells were metabolically labeled with
[35S]methionine and [35S]cysteine for 30 min and chased for 1 and 3 h.
Cells were lysed with 1% digitonin lysis buffer, and radioactively labeled
lysates were used for immunoprecipitation with an anti-Iga or anti-Igb
antibody. Anti-Iga or anti-Igb immunoprecipitates were untreated (2)
or treated (1) with Endo H before SDS-PAGE. Asterisks indicate the
Endo H–sensitive forms of m, Iga, and Igb. The data were reproduced in
three independent experiments.
Figure 9. K1 localization. Expression vector containing (A) the flag-K1
or (B) the K1-myc was electroporated into BJAB cells. After 48 h, cells
were fixed and reacted with mouse monoclonal anti-flag antibody (A) or
anti-myc antibody (B). K1 protein was detected with anti–mouse second-
ary antibody conjugated with Alexa 568 (red). The ER and Golgi com-
partment were detected with Alexa 488–conjugated Con A (green) and
BODIPY C5FL-ceramide (green), respectively. Localization of fluores-
cently labeled antibodies was visualized with a Leica TCS-SP laser scan-
ning microscope. Yellow color indicates colocalization of the red and
green labels. The data were reproduced in two independent experiments.18 Downregulation of BCR Complexes by KSHV K1
2 d after transfection, cells were stained with anti-flag, anti-
myc, or anti-CD4 antibody, followed by an Alexa 568–
conjugated secondary antibody (red). In addition, Alexa
488–conjugated (green) Con A was used for ER-specific
staining, and BODIPY C5FL-ceramide was used for Golgi
compartment–specific staining. The confocal microscopy
analysis showed that the K1 protein was predominantly lo-
calized in the ER, not in the Golgi compartment, whereas
z10–20% of the K1 protein was detected in plasma mem-
brane (Fig. 9). In striking contrast, .80% of CD4 was de-
tected in the plasma membrane under the same conditions
(data not shown). These results demonstrate that K1 is pri-
marily localized in the ER, and only a portion of K1 is
translocated into the plasma membrane.
Interaction of the NH2-terminal Region of K1 with the m
Chains. Because K1 downregulates BCR in a specific
manner, is primarily localized in the ER, and its NH2-ter-
minal region is necessary for BCR downregulation, we hy-
pothesized that the NH2-terminal region of K1 interacted
with BCR components and that this interaction led to their
retention in the ER. To test this hypothesis, BJAB cells
were transfected with expression vector containing a full-
length flag-tagged K1 gene. 48 h after transfection, cells
were lysed by 1% NP-40 detergent, followed by immuno-
precipitation with an anti-flag antibody. Polypeptides
present in anti-flag immune complexes were separated by
SDS-PAGE, transferred to nitrocellulose, and reacted with
an antibody specific for m chains, Iga or Igb. These exper-
iments showed that m chains were readily detected in K1
immune complexes, whereas Iga and Igb were not de-
tected at appreciable levels (Fig. 10 A; data not shown). We
further investigated whether K1 was capable of interacting
with the m chains in the absence of other BCR subunits.
To test this, the flag-tagged K1 and the m expression vec-
tors were transfected into the human 293 epithelial cell
line. Immune complexes of an anti-flag antibody or anti-m
antibody were immunoblotted with anti-m antibody and
anti-flag antibodies. These experiments demonstrated that
K1 was capable of interacting with the m chains in the ab-
sence of other BCR subunits (Fig. 10 B).
Figure 10. Interaction of K1
with m chains of BCR. (A) In-
teraction of K1 protein with m
chains in BJAB cells. BJAB cells
were transfected with pDEF3
vector or pDEF3 vector contain-
ing the flag-tagged K1. Cell ly-
sates were used for precipitation
(IP) with an anti-flag antibody,
followed by an immunoblot (IB)
with an anti-m antibody. Whole
cell lysates (WCL) of transfected
cells were included as controls.
Arrow indicates the m chain. (B)
Interaction of K1 protein with m
chains in the absence of other
BCR components. 293 cells
were transfected with expression
vector containing the flag-tagged
K1 and/or expression vector
containing human m chain
cDNA as indicated at the bottom
of the figure. Cell lysates were
used for precipitation (IP) with
an anti-flag antibody or anti-m
antibody, followed by an immu-
noblot (IB) with anti-flag and
anti-m chain antibodies. Whole cell lysates (WCL) of transfected cells were included as controls. Arrow indicates the m chain and the flag-tagged K1, and
the asterisk indicates the heavy chain of antibody. All data were reproduced in at least two independent experiments.
Figure 11. Interaction of the NH2-terminal region of K1 with m
chains. BJAB cells were transfected with expression vector containing
GST or K1/GST. Cell lysates were used for pull-down assay with glu-
tathione beads, followed by an immunoblot (IB) with an anti-m chain
antibody (left). Whole cell lysates (WCL) of transfected cells were in-
cluded as controls. The expression level of GST-AU1 and K1/GST-
AU1 in GST pull-down complexes was demonstrated by immunoblot
with an anti-AU1 antibody (right). Arrows indicate the m chain, GST-
AU1, and K1/GST-AU1 protein. The data were reproduced in two in-
dependent experiments.19 Lee et al.
To further demonstrate the interaction of the NH2-ter-
minal region of K1 with m chains, we constructed a K1/
GST-AU1 fusion mammalian expression plasmid in which
the NH2-terminal region of K1 containing seven potential
N-glycosylation sites was fused in frame into GST-AU1.
After transfection of a K1/GST-AU1 expression vector
into BJAB cells, glycosylated K1/GST-AU1 fusion com-
plexes were purified from cell lysates by glutathione affinity
chromatography and separated by SDS-PAGE, followed by
immunoblot analysis with an antibody specific for a m
chain. These experiments showed that K1/GST-AU1 in-
teracted with m chains, whereas GST-AU1 did not (Fig.
11). This result indicates that the NH2-terminal region of
K1 specifically interacts with m chains of BCR complexes,
and that this interaction is likely responsible for the ER re-
tention of BCR complexes.
Discussion
We and others have previously demonstrated the signal
transducing and transforming ability of K1 (19, 23, 24). In
this report, we further demonstrate that K1 expression spe-
cifically induces downregulation of BCR surface expres-
sion. The interaction of the NH2-terminal region of K1
with the m chains of BCR complexes likely retains these
complexes in the ER, resulting in downregulation of their
surface expression. These results indicate that a KSHV K1
transforming protein is capable of eliciting cellular signal
transduction as well as of inhibiting intracellular transport of
BCR. Both activities of K1 may be necessary to provide an
advantageous environment for virus-infected cells in vivo.
Association of newly synthesized m chain of BCR mole-
cules with Iga and Igb is essential for their intracellular
transport and plasma membrane deposition (3, 4). The pre-
dicted size and structure of the K1 has a significant resem-
blance to those of a single-domain Ig superfamily receptor
(19–22). In addition, similar to Iga and Igb, the cytoplas-
mic region of K1 contains a functional ITAM sequence
that is capable of transducing signals to elicit cellular activa-
tion events (23, 24). In this report, we further demonstrate
that, similar to Iga and Igb, the NH2-terminal region of
K1 interacts with m chains of BCR. Thus, KSHV K1 mim-
ics Iga and Igb in its ability to elicit signaling and to inter-
act with m chains of BCR. However, unlike Iga and Igb,
which interact with m chains to direct the BCR complexes
to the cell surface, K1 inhibits the intracellular transport of
BCR complexes to the cell surface. Mutational analysis
showed that although the K1/CD8-Tm chimera and K1
mutants dramatically downregulated BCR, their level of
downregulation was slightly lower compared with wild-
type K1. This may be because in the K1/CD8 chimera and
K1 mutants the NH2-terminal region of K1 is not properly
exposed to interact with the m chains. Nonetheless, our
study provides evidence for a functional role of the NH2-
terminal region of K1 in recruitment of m chains of BCR.
Similar to Ig, the NH2-terminal region of K1 contains
conserved hypervariable and Ig homologous domains.
Based on the predicted sequence, K1 is expected to be pri-
marily present in the plasma membrane. However, to our
surprise, most K1 was localized in the ER. Some of these
distinctive domains at the NH2-terminal region of K1 may
contribute to the ER localization and to the interaction
with m chains of BCR. Further detailed study is needed to
define the specific region of K1 required for these activities.
The downregulation of MHC class I and II molecules in
virus-infected or transformed cells is a well-established phe-
nomenon and often involves attenuation of transcription of
the genes encoding the class I subunits (29). In addition, a
postranslational mechanism of downregulation has been
described and includes the production of proteins that me-
diate retention of newly synthesized class I molecules in the
ER (29). Adenovirus E3 19K, human CMV US3, and
mouse CMV m152 retain MHC class I heavy chain in the
ER, preventing the maturation and intracellular transport
of heavy chains to the cell surface (30–33). This activity has
been shown to be mediated by interaction of these viral
glycoproteins with the class I heavy chain. In a similar way,
an interaction of K1 with m (heavy) chains retains BCR
complexes in the ER, preventing the maturation and intra-
cellular transport of BCR to the cell surface. In addition,
several ER-resident proteins including calnexin, calreticu-
lin, and Ig heavy chain binding protein have been shown
to be important for the assembly and intracellular transport
of multimeric protein complexes, including BCR (7, 8, 34,
35). Interaction of K1 with m chains may affect activity of
these ER-resident chaperons, which leads to accumulation
of the BCR complexes in the ER. An investigation of the
detailed molecular mechanisms of the ER retention of
BCR by K1 is currently underway.
What are the advantages of BCR downregulation to the
virus? BCR downregulation has already been demonstrated
in several human cancers. For example, .80% of the cases
of B cell chronic lymphocytic leukemia, the most common
hematologic malignancy in adulthood, and a large number
of AIDS-associated B cell lymphomas and mediastinal large
B cell lymphomas have been shown to have dramatically
decreased levels of BCR surface expression or diminished
protein tyrosine kinase activity associated with BCR (36–
40). In fact, KSHV-infected PEL cells that are of B cell or-
igin have no detectable level of surface expression of BCR
(41). These alterations have been shown to lead to nonre-
sponsiveness to BCR signaling (42). Because engagement
of the BCR initiates multiple intracellular signals that often
lead to apoptosis, an inhibition of BCR-mediated signaling
by the downregulation of its surface expression or reduc-
tion of BCR-associated protein tyrosine kinase activity
may provide a long-term survival advantage in vivo. EBV
latent membrane protein 2A (LMP2A) and KSHV K15
have also been shown to downregulate BCR function, but
in a different way from K1 (43–45). The NH2-terminal
ITAM of LMP2A and the COOH-terminal signaling
modules of K15 interact with the B cell tyrosine kinases lyn
and syk, and this interaction negatively modulates BCR
signal transduction (43–46). In addition, a recent study
with transgenic mice has demonstrated that LMP2A pro-
vides a constitutive survival signaling activity in primary B20 Downregulation of BCR Complexes by KSHV K1
cells of transgenic mice (47). Thus, we hypothesize that the
KSHV K1 may allow cell growth transformation to pro-
ceed by eliciting signals through its ITAM sequence, while
at the same time preventing potential adverse effects that
may be associated with apoptosis or untimely viral replica-
tion. In parallel with this hypothesis, K1 gene is expressed
at low levels of latently infected PEL, whereas its expres-
sion is significantly induced during viral lytic life cycle (20).
Thus, a detailed study of alterations of cellular signal trans-
duction and intracellular transport by KSHV K1 will not
only lead to a better understanding of viral persistence and
pathogenesis, but will also provide a novel means for inves-
tigating cellular regulatory systems.
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